Related Experiment Video
Updated: Apr 16, 2026

Isolation of Whole Cell Protein Lysates from Mouse Facial Processes and Cultured Palatal Mesenchyme Cells for Phosphoprotein Analysis
Published on: April 1, 2022
Expression of RUNX2 and its signaling partners TCF7, FGFR1/2 in cleidocranial dysplasia
Elżbieta Pawłowska1, Katarzyna A Wójcik2, Ewelina Synowiec2
1Department of Orthodontics, Medical University of Lodz, Łódź, Poland.
Abstract:
RUNX2 is a member of the PEBP2/CBF transcription factors family controlling the expression of genes whose products are essential for bone formation. Mutations in the RUNX2 gene may be associated with cleidocranial dysplasia (CCD), a rare skeletal disease characterized by stature aberrations, delayed closure of the cranial sutures, hypoplastic or aplastic clavicles, and multiple dental abnormalities. As RUNX2 is involved in many signaling pathways, we hypothesize that CCD may be associated with their changes. We determined the expression of RUNX2 and its signaling partners TCF7, involved in canonical Wnt signaling, and fibroblast growth factor receptors, FGFR1 and FGFR2 in periodontum of CCD patients and control individuals. We did not observe any differences between the level of RUNX2, TCF7 and FGFR1/2 mRNA, determined by real-time PCR, in CDD patients and controls. Therefore, RUNX2 signaling pathways with their partners TCF7 and FGFR1/2 may not be involved in CCD pathogenesis.
Insights
RUNX2 gene mutations can cause cleidocranial dysplasia (CCD), a skeletal disorder. This study found no differences in RUNX2 or its signaling partners in CCD patients, suggesting these pathways are not involved in CCD development.
Area of Science:
- Genetics
- Molecular Biology
- Skeletal Biology
Background:
- RUNX2 is a key transcription factor for bone formation.
- Mutations in RUNX2 are linked to cleidocranial dysplasia (CCD), a skeletal disorder.
- CCD presents with skeletal and dental abnormalities.
Purpose of the Study:
- To investigate the role of RUNX2 signaling pathways in CCD pathogenesis.
- To examine the expression of RUNX2, TCF7 (Wnt signaling), and FGFR1/2 in CCD patients.
- To determine if alterations in these pathways contribute to CCD.
Main Methods:
- Quantitative real-time PCR was used to measure mRNA levels.
- Expression of RUNX2, TCF7, FGFR1, and FGFR2 was analyzed.
- Samples were obtained from periodontium of CCD patients and control individuals.
Main Results:
- No significant differences were observed in RUNX2 mRNA levels between CCD patients and controls.
- Expression levels of TCF7 and FGFR1/2 mRNA were also similar in both groups.
- This indicates no major changes in the studied RUNX2 signaling components.
Conclusions:
- The investigated RUNX2 signaling pathways involving TCF7 and FGFR1/2 do not appear to be significantly altered in CCD.
- These specific pathways may not play a direct role in the pathogenesis of cleidocranial dysplasia.
- Further research may be needed to explore other potential molecular mechanisms in CCD.
More Related Videos
09:16Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells
Published on: September 1, 2019
09:07Dissection of Xenopus laevis Neural Crest for in vitro Explant Culture or in vivo Transplantation
Published on: March 4, 2014
Related Concept Videos
Determination
Notch Signaling Pathway
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not...
Hedgehog Signaling Pathway
TGF - β Signaling Pathway
Pleiotropy
Canonical Wnt Signaling Pathway